Clin Mol Hepatol.
2016 Dec;22(4):439-442. 10.3350/cmh.2016.0108.
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
- Affiliations
-
- 1Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea. drsong8177@naver.com
- KMID: 2373147
- DOI: http://doi.org/10.3350/cmh.2016.0108
Abstract
- No abstract available.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
- Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
- Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
- Lamivudine and adefovir combination therapy in lamivudine-resistant HBeAg-positive chronic hepatitis B patients
- Lamivudine and adefovir combination therapy in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B
